Bayer pondering Boots OTC buy?
This article was originally published in The Rose Sheet
Executive Summary
German drugmaker may consider acquiring Boots Healthcare International, Bayer CEO Werner Wenning says during Aug. 10 earnings call. "We never comment on a specific transaction...[but] we are always looking in all our areas behind directive targets to increase our position in specific markets," exec states, adding "the consumer care market is an attractive market and an important market for us, and if [BHI] is available in reasonable terms, of course we are interested." Boots the Chemists announced plans to divest its consumer health care business this spring (1"The Rose Sheet" April 11, 2005, p. 9). GlaxoSmithKline also has been mentioned as a potential buyer...